Sidewinder Therapeutics https://validator.w3.org/feed/docs/rss2.html Privacy Notice Home Eric Murphy, Ph.D. Eric Murphy, Ph.D. Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer Lonza’s Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next‑Generation Bispecific ADCs Terms of Use Adam Cotton, Ph.D. John Hamer, Ph.D. Ryan Corcoran, M.D., Ph.D. Daniel Estes, Ph.D. Carl Gordon, Ph.D., C.F.A. Josh Richardson, M.D. Sitemap Michael Mueller Rob McRae